Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment of Newly Diagnosed Patients with High-Risk APL By Ogkologos - September 3, 2025 361 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the APOLLO study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR “My Heart Will Always Hurt”: How I Honor My Childhood Best... April 26, 2022 This Saturday: National Prescription Drug Take-Back Day October 22, 2020 Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following... April 2, 2024 Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... September 11, 2023 Load more HOT NEWS FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma Get the Most out of Seasonal Fruits! Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who... Learning From Being Lost
